Cassella James V 4

What Happened James V. Cassella, Chief Development Officer of Trevi Therapeutics (TRVI), was granted a derivative award on February 19, 2026 covering 215,000 shares. The transaction is reported as an award (code A) with a reported transaction price of $0.00, indicating a stock option/grant rather than an open-market purchase or sale. The filing does not state an immediate cash value or exercise details in the excerpt provided.

Key Details

• Transaction date: 2026-02-19 (Form 4 filed 2026-02-20; appears timely).
• Transaction type/code: Grant/Award (derivative), reported at $0.00.
• Shares underlying award: 215,000 common shares.
• Vesting: Per footnote F1, the 215,000 underlying shares vest in equal monthly installments through February 19, 2030, subject to continued service.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• No sale/exercise reported — this is a compensation award, not a realized disposition.

Context This was a time‑based option/award that gives the insider the right to acquire common stock in the future as it vests; it is not an immediate purchase or sale. Such grants are common executive compensation and do not, by themselves, indicate the insider bought or sold stock on the open market.